Premium
Coexistence of MACC 1 and NM 23‐H1 dysregulation and tumor budding promise early prognostic evidence for recurrence risk of early‐stage colon cancer
Author(s) -
Ozturk Ersin,
Aksoy Secil AK,
Ugras Nesrin,
Tunca Berrin,
Ceylan Serkan,
Tezcan Gulcin,
Yilmazlar Tuncay,
Yerci Omer,
Egeli Unal,
Cecener Gulsah
Publication year - 2018
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/apm.12801
Subject(s) - tumor budding , colorectal cancer , pathological , desmoplasia , medicine , metastasis , stage (stratigraphy) , budding , tumor progression , oncology , pathology , cancer , gastroenterology , cancer research , biology , lymph node metastasis , genetics , paleontology , pancreatic cancer
The tumor‐node‐metastasis ( TNM ) classification, the presence of a mucinous component, and signet ring cells are well‐known criteria for identifying patients at a high risk for recurrence and determining the therapeutic approach for early‐stage colon cancer ( eCC ). Nevertheless, recurrence can unexpectedly occur in some eCC cases after surgical resection. The aims of the present study were to evaluate the relation of dysregulated MACC 1, c‐ MET , and NM 23‐H1 expression with the histopathological features of tumors in recurrence formation in eCC cases. A total of 100 sporadic eCC patients without poor prognosis factors were evaluated in this study. The relationship between the altered expression of MACC 1 , c‐ MET , and NM 23‐H1 and pathological microenvironmental features, including the presence of tumor budding and desmoplasia, were assessed. The primary outcomes, including 5‐year overall survival ( OS ) and disease‐free survival ( DFS ), were also measured. Compared with nonrecurrent patients, the expression level of MACC 1 was 8.27‐fold higher, and NM 23‐H1 was 11.36‐fold lower in patients with recurrence during the 5‐year follow‐up (p = 0.0345 and p = 0.0301, respectively). In addition, the coexistence of high MACC 1 and low NM 23‐H1 expression and tumor budding was associated with short OS (p < 0.001). We suggest that the combination of reduced NM 23‐H1 , induced MACC 1 , and the presence of tumor budding are promising biomarkers for the prediction of recurrence and may aid the stratification of patients with stage II colon cancer for adjuvant chemotherapy.